Skip to main content

Advertisement

SpringerLink
Log in

Psychomotor performance in relation to acute oral administration of Δ9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects

  • ORIGINAL PAPER
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB1) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 ± 2.9 years, 12 male) by comparing Δ9-tetrahydrocannabinol (Δ9-THC) and standardized cannabis extract containing Δ9-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Δ9-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Δ9-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Δ9-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB1 receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB1 receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483–1486

    Article  PubMed  CAS  Google Scholar 

  2. Bisogno T, Hanus L, De Petrocelis L, Tehilibon S, Ponde DE, Brandi I, Moriello AS, Davies JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845–852

    Article  PubMed  CAS  Google Scholar 

  3. Bloom JS, Hynd GW (2005) The role of the corpus callosum in interhemispheric transfer of information: excitation or inhibition? Neuropsychol Rev 15:59–71

    Article  PubMed  Google Scholar 

  4. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218

    Google Scholar 

  5. Bornheim LM, Grillo MP (1998) Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol 11:1209–1216

    Article  PubMed  CAS  Google Scholar 

  6. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155–163

    PubMed  CAS  Google Scholar 

  7. Chan PK, Chan SC, Yung WH (1998) Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist. Neuroreport 9:671–675

    Article  PubMed  CAS  Google Scholar 

  8. Crow TJ, Colter N, Frith CD, Johnstone EC, Owens DGC (1989) Developmental arrest of cerebral asymmetries in early onset schizophrenia. Psychiatry Res 29:247–253

    Article  PubMed  CAS  Google Scholar 

  9. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15

    Article  PubMed  CAS  Google Scholar 

  10. Doty RW (1989) Schizophrenia: a disease of interhemispheric processes at forebrain and brainstem levels? Behav Brain Res 34:1–33

    Article  PubMed  CAS  Google Scholar 

  11. D’Souza DC (2007) Cannabinoids and psychosis. Int Rev Neurobiol 78:289–326

    Article  PubMed  CAS  Google Scholar 

  12. Emrich HM, Leweke FM, Schneider U (1997) Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 56:803–807

    Article  PubMed  CAS  Google Scholar 

  13. Flyckt L, Sydow O, Bjerkenstedt L, Edman G, Rydin E, Wiesel FA (1999) Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Psychiatry Res 86:113–129

    Article  PubMed  CAS  Google Scholar 

  14. Gold S, Arndt S, Nopoulos P, O’Leary DS, Andreasen NC (1999) Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry 156:1342–1348

    PubMed  CAS  Google Scholar 

  15. Goode DJ, Manning AA (1988) Specific imbalance of right and left sided motor neuron excitability in schizophrenia. J Neurol Neurosurg Psychiatry 51:626–629

    Article  PubMed  CAS  Google Scholar 

  16. Goode DJ, Manning AA, Middleton JF, Williams B (1981) Fine motor performance before and after treatment in schizophrenic and schizoaffective patients. Psychiatry Res 5:247–255

    Article  PubMed  CAS  Google Scholar 

  17. Gorynia I, Campman V, Uebelhack R (2003) Intermanual coordination in relation to different clinical subgroups in right-handed patients with schizophrenic and other psychotic disorders. Eur Arch Psychiatry Clin Neurosci 253:53–59

    Article  PubMed  Google Scholar 

  18. Gorynia I, Dudeck U, Neumärker KJ (1994) Instability in functional motor laterality of children and adolescents with endogenous psychosis and predominantly motor disturbances. Eur Arch Psychiatry Clin Neurosci 244:33–38

    Article  PubMed  CAS  Google Scholar 

  19. Gorynia I, Egenter D (2000) Intermanual coordination in relation to handedness, familial sinistrality and lateral preferences. Cortex 36:1–18

    Article  PubMed  CAS  Google Scholar 

  20. Gorynia I, Uebelhack R (1992) Functional motor asymmetries correlated with clinical findings in unmedicated schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 242:39–45

    Article  PubMed  CAS  Google Scholar 

  21. Grotenhermen F (2005) Cannabinoids. Curr Drug Targets CNS Neurol Disord 4:507–530

    Article  PubMed  CAS  Google Scholar 

  22. Günther W, Günther R, Eich FX, Eben E (1986) Psychomotor disturbances in psychiatric patients as a possible basis for new attempts at differential diagnosis and therapy. II. Cross validation study on schizophrenic patients: persistence of a “psychotic motor syndrome” as possible evidence of an independent biological marker syndrome for schizophrenia. Eur Arch Psychiatry Neurol Sci 235:301–308

    Article  PubMed  Google Scholar 

  23. Gupta S, Andreasen NC, Arndt S, Flaum M, Schultz SK, Hubbard WC, Smith M (1995) Neurological soft signs in neuroleptic-naive and neuroleptic treated schizophrenic patients and in normal comparison subjects. Am J Psychiatry 152:191–196

    PubMed  CAS  Google Scholar 

  24. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932–1936

    Article  PubMed  CAS  Google Scholar 

  25. Hokama H, Shenton ME, Nestor PG, Kikinis R, Levitt JJ, Metcalf D, Wible CG, O’Donnell BF, Jolesz FA, McCarley RW (1995) Caudate, putamen, and globus pallidus volume in schizophrenia: a quantitative MRI study. Psychiatry Res 61:209–229

    Article  PubMed  CAS  Google Scholar 

  26. Iversen L (2003) Cannabis and the brain. Brain 126:1252– 1270

    Article  PubMed  Google Scholar 

  27. Johns A (2001) Psychiatric effects of cannabis. Br J Psychiatry 178:116–122

    Article  PubMed  CAS  Google Scholar 

  28. Juckel G, Roser P, Nadulski T, Stadelmann AM, Gallinat J (2007) Acute effects of delta-9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res 97:109–117

    Article  PubMed  Google Scholar 

  29. Levander SE, Bartfai A, Schalling D (1985) Regional cortical dysfunction in schizophrenic patients studied by computerized neuropsychological methods. Percept Mot Skills 61:479–495

    PubMed  CAS  Google Scholar 

  30. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665–1669

    Article  PubMed  CAS  Google Scholar 

  31. Lezak MD (1995) Neuropsychological assessments, 3rd edn. Oxford University Press, New York

    Google Scholar 

  32. Martinez-Arevalo MJ, Calcedo-Ordonez A, Varo-Prieto JR (1994) Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry 164:679–681

    Article  PubMed  CAS  Google Scholar 

  33. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564

    Article  PubMed  CAS  Google Scholar 

  34. Mechoulam R, Gaoni Y (1965) A total synthesis of delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87:3273–3275

    Article  PubMed  CAS  Google Scholar 

  35. Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S–19S

    PubMed  CAS  Google Scholar 

  36. Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM (2005) Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit 27:799–810

    Article  PubMed  CAS  Google Scholar 

  37. Oldfield RC (1971) The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9:97–113

    Article  PubMed  CAS  Google Scholar 

  38. Pelletier J, Suchet L, Witjas T, Habib M, Guttmann CR, Salamon G, Lyon-Caen O, Chérif AA (2001) A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 58:105–111

    Article  PubMed  CAS  Google Scholar 

  39. Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215

    Article  PubMed  CAS  Google Scholar 

  40. Pycock CJ, Kilpatric IC (1989) Motor asymmetries and drug effects: behavioral analyses of receptor activation. In: Boulton AA, Baker GB, Greenshaw AJ (eds) Neuromethods, vol 13: psychopharmacology. Human Press, Clifton, pp 1–93

    Google Scholar 

  41. Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, Navarro M (1998) Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5:483–501

    Article  PubMed  CAS  Google Scholar 

  42. Rodriguez de Fonseca F, Gorriti MA, Bilbao A, Escuredo L, Garcia-Segura LM, Piomelli D, Navarro M (2001) Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson’s disease and schizophrenia. Neurotox Res 3:23–35

    PubMed  CAS  Google Scholar 

  43. Roser P, Vollenweider FX, Kawohl W (2008) Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry 7:1–12. DOI: 10.1080/15622970801908047

    Google Scholar 

  44. Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM (2008) Effects of acute oral Delta(9)-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol 18:569–577

    Article  PubMed  CAS  Google Scholar 

  45. Roser P, Stadelmann AM, Arning L, Gallinat J, Epplen JT, Juckel G (2008) Acute effects of Δ9-tetrahydrocannabinol on the auditory event-related mismatch negativity depending on genetic variations in the dysbindin, neuregulin and G72 gene. Int J Neuropsychopharmacol 11(Suppl 1):256

    Google Scholar 

  46. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101

    Article  PubMed  CAS  Google Scholar 

  47. Sañudo-Peña MC, Romero J, Seale GE, Fernandez-Ruiz JJ, Walker JM (2000) Activational role of cannabinoids on movement. Eur J Pharmacol 391:269–274

    Article  PubMed  Google Scholar 

  48. Sañudo-Peña MC, Tsou K, Walker JM (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65:703–713

    Article  PubMed  Google Scholar 

  49. Sauerwein HC, Lassonde M (1994) Cognitive and sensori-motor functioning in the absence of the corpus callosum: neuropsychological studies in callosal agenesis and callosotomized patients. Behav Brain Res 64:229–240

    Article  PubMed  CAS  Google Scholar 

  50. Schmidt SL, Oliveira RM, Krahe TE, Filgueiras CC (2000) The effects of hand preference and gender on finger tapping performance asymmetry by the use of an infra-red light measurement device. Neuropsychologia 38:529–534

    Article  PubMed  CAS  Google Scholar 

  51. Shakow D, Huston PE (1936) Studies on motor function in schizophrenia: I. Speed of tapping. J Gen Psychol 15:63–106

    Google Scholar 

  52. Shaw JC, Colter N, Resek G (1983) EEG coherence, lateral preference and schizophrenia. Psychol Med 13:299–306

    Article  PubMed  CAS  Google Scholar 

  53. Shimoyama I, Ninchoji T, Uemura K (1990) The finger-tapping test. A quantitative analysis. Arch Neurol 47:681–684

    PubMed  CAS  Google Scholar 

  54. Solowij N (1998) Cannabis and cognitive functioning. Cambridge University Press, Cambridge

    Google Scholar 

  55. Stratta P, Rossi A, Gallucci M, Amicarelli I, Passariello R, Casacchia M (1989) Hemispheric asymmetries and schizophrenia: a preliminary magnetic resonance imaging study. Biol Psychiatry 25:275–284

    Article  PubMed  CAS  Google Scholar 

  56. Strik W, Dierks T (2008) Neurophysiological mechanisms of psychotic symptoms. Eur Arch Psychiatry Clin Neurosci 258(Suppl 5):66–70

    Article  PubMed  Google Scholar 

  57. Struve FA, Straumanis JJ, Patrick G (1994) Persistent topographic quantitative EEG sequelae of chronic marihuana use: a replication study and initial discriminant function analysis. Clin Electroencephalogr 25:63–75

    PubMed  CAS  Google Scholar 

  58. Struve FA, Straumanis JJ, Patrick G, Leavitt J, Manno JE, Manno BR (1999) Topographic quantitative EEG sequelae of chronic marihuana use: a replication using medically and psychiatrically screened normal subjects. Drug Alcohol Depend 56:167–179

    Article  PubMed  CAS  Google Scholar 

  59. Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C (2000) Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 97:89–97

    Article  PubMed  CAS  Google Scholar 

  60. Torrey E (1980) Neurological abnormalities in schizophrenic patients. Biol Psychiatry 15:381–388

    PubMed  CAS  Google Scholar 

  61. Turner WM, Tsuang MT (1990) Impact of substance abuse on the course and outcome of schizophrenia. Schizophr Bull 16:87–95

    PubMed  CAS  Google Scholar 

  62. Wobrock T, Sittinger H, Behrendt B, D’Amelio R, Falkai P, Caspari D (2007) Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 257:203–210

    Article  PubMed  Google Scholar 

  63. Woodruff PW, McManus IC, David AS (1995) Meta-analysis of corpus callosum size in schizophrenia. J Neurol Neurosurg Psychiatry 58:457–461

    Article  PubMed  CAS  Google Scholar 

  64. Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H] SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:355–360

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Institute for Clinical Research, Berlin, Germany.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Ruhr-University Bochum, Alexandrinenstr. 1, 44791, Bochum, Germany

    Patrik Roser & Georg Juckel

  2. Department of Psychiatry, Charité University Hospital, 10117, Berlin, Germany

    Jürgen Gallinat, Gordon Weinberg, Inge Gorynia & Andreas M. Stadelmann

Authors
  1. Patrik Roser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jürgen Gallinat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gordon Weinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georg Juckel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Inge Gorynia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andreas M. Stadelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrik Roser.

Additional information

I. Gorynia and A.M. Stadelmann have equally contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roser, P., Gallinat, J., Weinberg, G. et al. Psychomotor performance in relation to acute oral administration of Δ9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. Eur Arch Psychiatry Clin Neurosci 259, 284–292 (2009). https://doi.org/10.1007/s00406-009-0868-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-009-0868-5

Keywords

Search

Navigation